TY - JOUR
T1 - Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile
AU - González-Martín, Antonio
AU - Alba, Emilio
AU - Ciruelos, Eva
AU - Cortés, Javier
AU - Llombart, Antonio
AU - Lluch, Ana
AU - Andrés, Raquel
AU - Álvarez, Isabel
AU - Aramendía, José Manuel
AU - de la Peña, Francisco Ayala
AU - Barnadas, Agustí
AU - Batista, Norberto
AU - Calvo, Lourdes
AU - Galve, Elena
AU - García-Palomo, Andrés
AU - García-Sáenz, José Ángel
AU - de la Haba, Juan
AU - López, Rafael
AU - López-Vivanco, Guillermo
AU - Martínez-Jáñez, Noelia
AU - de Dueñas, Eduardo Martínez
AU - Plazaola, Arrate
AU - Rodríguez-Lescure, Álvaro
AU - Ruiz, Manuel
AU - Sánchez-Rovira, Pedro
AU - Santaballa, Ana
AU - Seguí, Miguel Ángel
AU - Tusquets, Ignasi
AU - Zamora, Pilar
AU - Martín, Miguel
PY - 2016/6/1
Y1 - 2016/6/1
N2 - © 2016 Bentham Science Publishers. Around 40% of patients with breast cancer will present with a recurrence of the disease. Chemotherapy is recommended for patients with recurrent hormone-independent or hormone-refractory breast cancer and almost all patients with metastatic breast cancer (MBC) receive chemotherapy during their medical history. Nanoparticle albuminbound (nab)-paclitaxel is a solvent-free, 130-nanometer particle formulation of paclitaxel. Nab-paclitaxel can be administered to all patients for whom the treatment choice is a taxane. In this review, 6 patient profiles for which nabpaclitaxel may be particularly useful are described and analyzed: (i) as first-line treatment of MBC, (ii) as second-line treatment of MBC after oral chemotherapy, (iii) after a standard taxane, (iv) as third-line treatment after a standard taxane and oral chemotherapy, (v) for patients with HER2-positive MBC and (vi) for patients with intolerance to standard taxanes. Nab-paclitaxel is a rational treatment choice for patients with MBC in different settings, as well as for those with prior exposure to a standard taxane.
AB - © 2016 Bentham Science Publishers. Around 40% of patients with breast cancer will present with a recurrence of the disease. Chemotherapy is recommended for patients with recurrent hormone-independent or hormone-refractory breast cancer and almost all patients with metastatic breast cancer (MBC) receive chemotherapy during their medical history. Nanoparticle albuminbound (nab)-paclitaxel is a solvent-free, 130-nanometer particle formulation of paclitaxel. Nab-paclitaxel can be administered to all patients for whom the treatment choice is a taxane. In this review, 6 patient profiles for which nabpaclitaxel may be particularly useful are described and analyzed: (i) as first-line treatment of MBC, (ii) as second-line treatment of MBC after oral chemotherapy, (iii) after a standard taxane, (iv) as third-line treatment after a standard taxane and oral chemotherapy, (v) for patients with HER2-positive MBC and (vi) for patients with intolerance to standard taxanes. Nab-paclitaxel is a rational treatment choice for patients with MBC in different settings, as well as for those with prior exposure to a standard taxane.
KW - Capecitabine
KW - Chemotherapy
KW - Docetaxel
KW - MBC
KW - Nab-paclitaxel
KW - Paclitaxel
M3 - Article
SN - 1568-0096
VL - 16
SP - 415
EP - 428
JO - Current Cancer Drug Targets
JF - Current Cancer Drug Targets
IS - 5
ER -
